Trial Profile

The Effects of Dupilumab on Allergic Contact Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary)
Indications Allergic contact dermatitis
Focus Therapeutic Use

Most Recent Events

12 Feb 2025 Planned End Date changed from 1 Dec 2023 to 31 Jul 2025.
12 Feb 2025 Status changed from recruiting to active, no longer recruiting.
29 Oct 2023 The study protocol amended since the investigators will recruit 30 patients (previously 20 patients) with allergic contact dermatitis who have not improved with allergen avoidance up to 18 months (previously 6 months) after patch testing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com